Recently, Wondfo's wholly-owned subsidiary in the United States, Wondfo USA Co., Ltd. (hereinafter referred to as the "Wondfo USA"), received notification from the U.S. Food and Drug Administration (FDA) that the Wondfo USA's WELLlife™ COVID-19 / Influenza A&B Home Test for the SARS-COV-2 viruses, influenza A virus, and influenza B virus, has obtained Emergency Use Authorization from FDA (EUA240011).

 
One Sample, Three Results, Easy and Fast
 

Respiratory virus infections caused by influenza A, influenza B, or the SARS-COV-2 viruses exhibit similar clinical manifestations. Based on lateral flow immunoassay, Wondfo USA’s WELLlife™ COVID-19 / Influenza A&B Home Test is easy to operate. Adding one sample, three results can be obtained in 10 minutes. It features a long detection window, built-in quality control line, and fast result show. Only an anterior nasal sample is needed for a qualitative testing within 5 days of symptom onset.

Based on the independent evaluation results by the FDA, third-party laboratory research, clinical trial, and usability study among the general population, Wondfo USA’s WELLlife™ COVID-19 / Influenza A&B Home Test has been proven to be safe, effective, simple to use, suitable for at-home testing in regular households, and appropriate for the use by individuals aged two and above. Clinical validation data shows that the test has a specificity of 99.7% compared to PCR results, and the sensitivity has far exceeded the FDA requirement of 80%.

 
In conclusion, the WELLlife™ COVID-19 / Influenza A&B Home Test features below advantages:

• Suitable for testing respiratory patients aged two and above

• Suitable for testing patients with respiratory symptoms within 5 days

• Simple sampling with anterior nasal swab

• With only one sample added, it can simultaneously test for the SARS-COV-2 viruses, influenza A, and influenza B

• Results available in 10 minutes

• Good product performance, with high clinical validation showing a high correlation between test results and laboratory testing

 
Building a Defense Line for Life with Technology
Fight Infectious Diseases together
 

To help early detection, diagnosis, and treatment of respiratory infectious diseases, Wondfo Biotech integrates multiple technology platforms, including colloidal gold, fluorescence immunoassay, chemiluminescence, electrochemistry, molecular diagnostics, etc., developing a one-stop respiratory infection testing solution from pathogen to serology, which can timely and effectively assist in the differential diagnosis and treatment of common respiratory diseases.

To rapidly identify infection types, Wondfo’s colloidal gold technology platform can provide rapid testing products for the SARS-COV-2 viruses and influenza A and B, mycoplasma/chlamydia pneumonia, etc., with simple operation and results available in 15 minutes.

For assessing the severity of infection, evaluating antibiotic efficacy, etc., Wondfo Biotech has achieved a leading coverage of inflammatory biomarkers domestically based on the dual platform of immunofluorescence and chemiluminescence, continuously iterated and upgraded to effectively assist in determining the severity of infection and prevent antibiotic misuse. Wondfo Biotech’s immunofluorescence strip enables fully automated micro blood testing of complete blood routine and four inflammation items with just one blood sample, requiring a minimum sample volume of only 8.5 microliters, providing quantitative results in 3-15 minutes. The chemiluminescence platform has high efficiency per unit area, good stability, precision, and repeatability, capable of detecting subtle concentration changes to aid in accurate diagnosis.

From HIV, SARS, influenza A and B, H7N9 to COVID-19, Wondfo has always been actively involved in global public health emergency responses, using technology to support epidemic prevention and control. Wondfo will continue promoting scientific research innovation, collaborating with global organizations to combat threats to human health posed by infectious diseases.